tbuckley/cabot-search huggingface dataset:
<scp>Adipose‐Derived</scp> Regenerative Cell Transplantation for the Treatment of Hand Dysfunction in Systemic Sclerosis: A Randomized Clinical Trial
Authors: Dinesh Khanna, Paul Caldron, Richard W. Martin, Suzanne Kafaja, Robert Spiera, Shadi Shahouri, Ankoor Shah, Vivien Hsu, John Ervin, Robert Simms, Robyn T. Domsic, Virginia Steen, Laura K. Hummers, Chris Derk, Maureen Mayes, Soumya Chatterjee, John Varga, Steven Kesten, John K. Fraser, Daniel E. Furst
Journal: Arthritis & Rheumatology (2022)

Hand dysfunction is common in systemic sclerosis (SSc). We undertook this study to evaluate the capacity of autologous adipose-derived regenerative cells (ADRCs) to improve hand function in SSc patients.The Scleroderma Treatment with Celution Processed Adipose Derived Regenerative Cells Trial was a prospective, randomized, double-blind trial of ADRCs, in which ADRCs were obtained from patients with SSc by small-volume adipose tissue harvest, and the fingers of each patient were injected with ADRCs. The primary end point was change in hand function at 24 and 48 weeks, assessed using the Cochin Hand Function Scale (CHFS). One of the secondary end points included the change in Health Assessment Questionnaire disability index (HAQ DI) at 48 weeks. Separate prespecified analyses were performed for patients with diffuse cutaneous SSc (dcSSc) and those with limited cutaneous SSc (lcSSc).Eighty-eight patients were randomized to receive ADRCs (n = 48 [32 patients with dcSSc and 16 with lcSSc]) or placebo (n = 40 [19 patients with dcSSc and 21 with lcSSc]). Change in hand function according to CHFS score was numerically higher for the ADRC group compared to the placebo group but did not achieve statistical significance (mean ± SD improvement in the CHFS score at 48 weeks 11.0 ± 12.5 versus 8.9 ± 10.5; P = 0.299). For patients with dcSSc, the between-group difference in the CHFS at 48 weeks was 6.3 points (nominal P = 0.069). For the secondary end point, the dcSSc group exhibited a between-group difference of 0.17 points in the HAQ DI (nominal P = 0.044) at 48 weeks. Of the ADRC-treated patients with dcSSc, 52% reported improvement greater than the minimum clinically important difference for both CHFS and HAQ DI compared to 16% in the placebo group (nominal P = 0.016). Small-volume adipose tissue harvest and ADRC treatment were well tolerated.While the primary end point of this trial was not achieved, efficacy trends were observed in patients with dcSSc. Adipose tissue harvest and ADRC injection were demonstrated to be feasible. Further clinical trials of this intervention in the setting of dcSSc are warranted.
Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, <i>IDH</i>-wildtype: <i>Post Hoc</i> Analysis of the EORTC Randomized Phase III CATNON Trial
Authors: C. Mircea S. Tesileanu, Marc Sanson, Wolfgang Wick, Alba A. Brandes, Paul M. Clement, Sara C. Erridge, Michael A. Vogelbaum, Anna K. Nowak, Jean-Francois Baurain, Warren P. Mason, Helen Wheeler, Olivier L. Chinot, Sanjeev Gill, Matthew Griffin, Leland Rogers, Walter Taal, Roberta Rudà, Michael Weller, Catherine McBain, Myra E. van Linde, Kenneth Aldape, Robert B. Jenkins, Johan M. Kros, Pieter Wesseling, Andreas von Deimling, Youri Hoogstrate, Iris de Heer, Peggy N. Atmodimedjo, Hendrikus J. Dubbink, Rutger W.W. Brouwer, Wilfred F.J. van IJcken, Kin Jip Cheung, Vassilis Golfinopoulos, Brigitta G. Baumert, Thierry Gorlia, Pim J. French, Martin J. van den Bent
Journal: Clinical Cancer Research (2022)

Abstract Purpose: In a post hoc analysis of the CATNON trial (NCT00626990), we explored whether adding temozolomide to radiotherapy improves outcome in patients with IDH1/2 wildtype (wt) anaplastic astrocytomas with molecular features of glioblastoma [redesignated as glioblastoma, isocitrate dehydrogenase–wildtype (IDH-wt) in the 2021 World Health Organization (WHO) classification of central nervous system tumors]. Patients and Methods: From the randomized phase III CATNON study examining the addition of adjuvant and concurrent temozolomide to radiotherapy in anaplastic astrocytomas, we selected a subgroup of IDH1/2wt and H3F3Awt tumors with presence of TERT promoter mutations and/or EGFR amplifications and/or combined gain of chromosome 7 and loss of chromosome 10. Molecular abnormalities including MGMT promoter methylation status were determined by next-generation sequencing, DNA methylation profiling, and SNaPshot analysis. Results: Of the 751 patients entered in the CATNON study, 670 had fully molecularly characterized tumors. A total of 159 of these tumors met the WHO 2021 molecular criteria for glioblastoma, IDH-wt. Of these patients, 47 received radiotherapy only and 112 received a combination of radiotherapy and temozolomide. There was no added effect of temozolomide on either overall survival [HR, 1.19; 95% confidence interval (CI), 0.82–1.71] or progression-free survival (HR, 0.87; 95% CI, 0.61–1.24). MGMT promoter methylation was prognostic for overall survival, but was not predictive for outcome to temozolomide treatment either with respect to overall survival or progression-free survival. Conclusions: In this cohort of patients with glioblastoma, IDH-wt temozolomide treatment did not add benefit beyond that observed from radiotherapy, regardless of MGMT promoter status. These findings require a new well-powered prospective clinical study to explore the efficacy of temozolomide treatment in this patient population.
Studies of a mosaic patient with DBA and chimeric mice reveal erythroid cell–extrinsic contributions to erythropoiesis
Authors: Raymond T. Doty, Xing Fan, David J. Young, Jialiu Liang, Komudi Singh, Zahra Pakbaz, Ronan Desmond, Sara K. Young-Baird, Settara C. Chandrasekharappa, Frank X. Donovan, Susan R. Phelps, Thomas Winkler, Cynthia E. Dunbar, Janis L. Abkowitz
Journal: Blood (2022)
OUTCOMES FROM EARLY INITIATION OF MECHANICAL CIRCULATORY SUPPORT IN CARDIOGENIC SHOCK IN ACUTE MYOCARDIAL INFARCTION-AN ANALYSIS OF THE NATIONAL INPATIENT SAMPLE DATABASE (2015-2018)
Authors: Varun Victor, Harsh P. Patel, Kirolos Barssoum, Samarthkumar Thakkar, Ahmed Mohamed, Rohan Desai, Mohab Hassib, Sidakpal Panaich, Wissam Khalife
Journal: Journal of the American College of Cardiology (2022)
Treatment patterns and outcomes according to cytogenetic risk stratification in patients with multiple myeloma: a real-world analysis
Authors: Shebli Atrash, Evelyn M. Flahavan, Tao Xu, Esprit Ma, Sudeep Karve, Wan-Jen Hong, Gilbert Jirau-Lucca, Michael Nixon, Sikander Ailawadhi
Journal: Blood Cancer Journal (2022)

Abstract A clearer understanding of the prognostic implications of t(11;14) in multiple myeloma (MM) is needed to inform current and future therapeutic options. We utilized real-world data from a US database to examine treatment patterns and outcomes in patients by t(11;14) status compared with high- and standard-risk subgroups across different lines of therapy (LoT). This retrospective, observational cohort study used de-identified patient-level information from adults with MM and first-line treatment initiation between January 2011 and January 2020, followed until February 2020. The high-risk cohort comprised patients with high-risk genetic abnormalities per mSMART criteria (including those with co-occurring t(11;14)). Among 6138 eligible patients, 6137, 3160, and 1654 received first-, second-, and third-line treatments, respectively. Of 645 patients who had t(11;14), 69.1% had t(11;14) alone, while 30.9% had co-occurring high-risk abnormalities. Altogether, 1624 and 2544 patients were classified as high- and standard-risk, respectively. In the absence of biomarker-driven therapy, treatment patterns remain similar across LoT in high-risk, t(11;14)+, and standard-risk subgroups. Across all LoT, patient outcomes in the high-risk subgroup were less favorable than those in the t(11;14)+ and standard-risk subgroups. Thus, there is an opportunity for novel therapeutics targeted to t(11;14) and other defined subgroups to personalize MM therapy and optimize patient outcomes.
POSTERIOR WALL FIBROSIS IS CORRELATED WITH MORE SEVERE LEFT ATRIAL DYSFUNCTION
Authors: Yichi Zhang, Abdel Hadi El Hajjar, Mario Mekhael, Charbel Noujaim, Lilas Dagher, Aneesh Dhore-Patil, Alan Morris, Eugene G. Kholmovski, Chao Huang, Raman Danrad, Tarek Hassan Ayoub, Christopher Pottle, Nassir F. Marrouche
Journal: Journal of the American College of Cardiology (2022)
CGE22-096: Trends in The Use of Comprehensive Genomic Profiling Among Older Patients With Advanced Cancer From 2018 to 2020 in the United States: Findings From the SEQUENCE Study
Authors: Monica Chase, Yihua Xu, Eleanor O Caplan, Nicole Myer, Sheetal Sheth, Brandon T Suehs, Gboyega Adeboyeje
Journal: Journal of the National Comprehensive Cancer Network (2022)

"CGE22-096: Trends in The Use of Comprehensive Genomic Profiling Among Older Patients With Advanced Cancer From 2018 to 2020 in the United States: Findings From the SEQUENCE Study" published on 31 Mar 2022 by National Comprehensive Cancer Network.
INFLAMMATORY BURDEN AND RENAL FUNCTION DECLINE IN PATIENTS WITH STABLE CORONARY ARTERY DISEASE: A MULTI-CENTER COHORT STUDY
Authors: Ting-Wei Kao, Chin-Chou Huang, Hsin-Bang Leu, Wei-Hsian Yin, Wei-Kung Tseng, Yen-Wen Wu, Tsung-Hsien Lin, Hung-I Yeh, Kuan-Cheng Chang, Ji-Hung Wang, Chau-Chung Wu, Jaw-Wen Chen
Journal: Journal of the American College of Cardiology (2022)
PREDICTORS OF 30-DAY MORTALITY IN 2,155 PATIENTS WITH SURGICAL VALVE REPLACEMENTLOW-TO-MIDDLE-INCOME COUNTRY RESULTS
Authors: Ghazal Peerwani, Sana Sheikh, Saba Aijaz, Imran Ali, Ghufran Khan, Umer Darr, Madiha Ahmed, Asad Z. Pathan
Journal: Journal of the American College of Cardiology (2022)
What We Know and Don’t Know About Renal Denervation to Lower Blood Pressure
Authors: Katherine H. Chau, Michel Azizi, Ajay J. Kirtane
Journal: JAMA Cardiology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Activation of the zinc-sensing receptor GPR39 promotes T-cell reconstitution after hematopoietic cell transplant in mice
Authors: Lorenzo Iovino, Kirsten Cooper, Paul deRoos, Sinéad Kinsella, Cindy Evandy, Tamas Ugrai, Francesco Mazziotta, Kathleen S. Ensbey, David Granadier, Kayla Hopwo, Colton Smith, Alex Gagnon, Sara Galimberti, Mario Petrini, Geoffrey R. Hill, Jarrod A. Dudakov
Journal: Blood (2022)

Prolonged lymphopenia represents a major clinical problem after cytoreductive therapies such as chemotherapy and the conditioning required for hematopoietic stem cell transplant (HCT), contributing to the risk of infections and malignant relapse. Restoration of T-cell immunity depends on tissue regeneration in the thymus, the primary site of T-cell development, although the capacity of the thymus to repair itself diminishes over its lifespan. However, although boosting thymic function and T-cell reconstitution is of considerable clinical importance, there are currently no approved therapies for treating lymphopenia. Here we found that zinc (Zn) is critically important for both normal T-cell development and repair after acute damage. Accumulated Zn in thymocytes during development was released into the extracellular milieu after HCT conditioning, where it triggered regeneration by stimulating endothelial cell production of BMP4 via the cell surface receptor GPR39. Dietary supplementation of Zn was sufficient to promote thymic function in a mouse model of allogeneic HCT, including enhancing the number of recent thymic emigrants in circulation although direct targeting of GPR39 with a small molecule agonist enhanced thymic function without the need for prior Zn accumulation in thymocytes. Together, these findings not only define an important pathway underlying tissue regeneration but also offer an innovative preclinical approach to treat lymphopenia in HCT recipients.
Prevention and Early Identification of Eating Disorders
Authors: Evelyn Attia, Angela S. Guarda
Journal: JAMA (2022)

Cynthia Feltner, MD, MPH; Christine Peat, PhD; Shivani Reddy, MD, MS; Sean Riley, MA, MSc; Nancy Berkman, PhD; Jennifer Cook Middleton, PhD; Casey Balio, PhD; Manny Coker-Schwimmer, MPH; Daniel E. Jonas, MD, MPH
Early administration of tocilizumab in hospitalized COVID-19 patients with elevated inflammatory markers; COVIDSTORM—a prospective, randomized, single-centre, open-label study
Authors: Niklas Broman, Thijs Feuth, Tytti Vuorinen, Mika Valtonen, Ulla Hohenthal, Eliisa Löyttyniemi, Tiina Hirvioja, Päivi Jalava-Karvinen, Harri Marttila, Marika Nordberg, Jarmo Oksi
Journal: Clinical Microbiology and Infection (2022)

Severe COVID-19 is associated with an imbalanced immune response. We hypothesized that patients with enhanced inflammation, as demonstrated by increased levels of certain inflammatory biomarkers, would benefit from interleukin-6 blockage.Patients hospitalized with COVID-19, hypoxemia, and at least two of four markedly elevated markers of inflammation (interleukin-6, C-reactive protein, ferritin, and/or D-dimer) were randomized for tocilizumab (TCZ) plus standard of care (SoC) or SoC alone. The primary endpoint was clinical status at day 28 assessed using a seven-category ordinal scale, and the secondary endpoints included intensive care unit admission, respiratory support, and duration of hospital admission.Clinical status at day 28 was significantly better in patients who received TCZ in addition to SoC compared with those who received SoC alone (p = 0.037). By then, 93% of patients who received TCZ (n = 53 of 57) and 86% of control patients (n = 25 of 29) had been discharged from the hospital. In addition, 47% of TCZ patients (n = 27 of 57) and 24% of control patients (n = 7 of 29) had resumed normal daily activities. The median length of hospitalization was 9 days (interquartile range, 7-12) in the TCZ group and 12 days (interquartile range, 9-15) in the control group (p = 0.014).In patients hospitalized with COVID-19, hypoxemia, and elevated inflammation markers, administration of TCZ in addition to SoC was associated with significantly better clinical recovery by day 28 and a shorter hospitalization compared with SoC alone.
Enzyme-instructed self-assembly of peptide-drug conjugates in tear fluids for ocular drug delivery
Authors: Yuhan Hu, Yuan Wang, Jie Deng, Xiangyu Ding, Deqing Lin, Hui Shi, Lin Chen, Dan Lin, Yuqin Wang, Serhii Vakal, Jiaqing Wang, Xingyi Li
Journal: Journal of Controlled Release (2022)
Marginalized identities, mistreatment, discrimination, and burnout among US medical students: cross sectional survey and retrospective cohort study
Authors: Bethelehem G Teshome, Mayur M Desai, Cary P Gross, Katherine A Hill, Fangyong Li, Elizabeth A Samuels, Ambrose H Wong, Yunshan Xu, Dowin H Boatright
Journal: BMJ (2022)

Abstract Objective To describe the association between mistreatment, burnout, and having multiple marginalized identities during undergraduate medical education. Design Cross sectional survey and retrospective cohort study. Setting 140 US medical schools accredited by the Association of American Medical Colleges. Participants 30 651 graduating medical students in 2016 and 2017. Main outcome measures Self-reported sex, race or ethnicity, and sexual orientation groups were considered, based on the unique combinations of historically marginalized identities held by students. Multivariable linear regression was used to determine the association between unique identity groups and burnout along two dimensions (exhaustion and disengagement) as measured by the Oldenburg Burnout Inventory for Medical Students while accounting for mistreatment and discrimination. Results Students with three marginalized identities (female; non-white; lesbian, gay, or bisexual (LGB)) had the largest proportion reporting recurrent experiences of multiple types of mistreatment (88/299, P&lt;0.001) and discrimination (92/299, P&lt;0.001). Students with a higher number of marginalized identities also had higher average scores for exhaustion. Female, non-white, and LGB students had the largest difference in average exhaustion score compared with male, white, and heterosexual students (adjusted mean difference 1.96, 95% confidence interval 1.47 to 2.44). Mistreatment and discrimination mediated exhaustion scores for all identity groups but did not fully explain the association between unique identity group and burnout. Non-white and LGB students had higher average disengagement scores than their white and heterosexual counterparts (0.28, 0.19 to 0.37; and 0.73, 0.52 to 0.94; respectively). Female students, in contrast, had lower average disengagement scores irrespective of the other identities they held. After adjusting for mistreatment and discrimination among female students, the effect among female students became larger, indicating a negative confounding association. Conclusion In this study population of US medical students, those with multiple marginalized identities reported more mistreatment and discrimination during medical school, which appeared to be associated with burnout.
In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial
Authors: Irina Gurevich, Pooja Agarwal, PeiPei Zhang, John A. Dolorito, Stacie Oliver, Henry Liu, Nicholas Reitze, Nikhil Sarma, Isin Sinem Bagci, Kunju Sridhar, Visesha Kakarla, Vamsi K. Yenamandra, Mark O’Malley, Marco Prisco, Sara F. Tufa, Douglas R. Keene, Andrew P. South, Suma M. Krishnan, M. Peter Marinkovich
Journal: Nature Medicine (2022)

Abstract Recessive dystrophic epidermolysis bullosa (RDEB) is a lifelong genodermatosis associated with blistering, wounding, and scarring caused by mutations in COL7A1 , the gene encoding the anchoring fibril component, collagen VII (C7). Here, we evaluated beremagene geperpavec (B-VEC), an engineered, non-replicating COL7A1 containing herpes simplex virus type 1 (HSV-1) vector, to treat RDEB skin. B-VEC restored C7 expression in RDEB keratinocytes, fibroblasts, RDEB mice and human RDEB xenografts. Subsequently, a randomized, placebo-controlled, phase 1 and 2 clinical trial (NCT03536143) evaluated matched wounds from nine RDEB patients receiving topical B-VEC or placebo repeatedly over 12 weeks. No grade 2 or above B-VEC-related adverse events or vector shedding or tissue-bound skin immunoreactants were noted. HSV-1 and C7 antibodies sometimes presented at baseline or increased after B-VEC treatment without an apparent impact on safety or efficacy. Primary and secondary objectives of C7 expression, anchoring fibril assembly, wound surface area reduction, duration of wound closure, and time to wound closure following B-VEC treatment were met. A patient-reported pain–severity secondary outcome was not assessed given the small proportion of wounds treated. A global assessment secondary endpoint was not pursued due to redundancy with regard to other endpoints. These studies show that B-VEC is an easily administered, safely tolerated, topical molecular corrective therapy promoting wound healing in patients with RDEB.
Quantitative Myocardial Perfusion Predicts Outcomes in Patients With Prior Surgical Revascularization
Authors: Andreas Seraphim, Benjamin Dowsing, Krishnaraj S Rathod, Hunain Shiwani, Kush Patel, Kristopher D Knott, Sameer Zaman, Ieuan Johns, Yousuf Razvi, Rishi Patel, Hui Xue, Daniel A Jones, Marianna Fontana, Graham Cole, Rakesh Uppal, Rhodri Davies, James C Moon, Peter Kellman, Charlotte Manisty
Journal: Journal of the American College of Cardiology (2022)
REAL-WORLD EXPERIENCE OF CORONARY COMPUTED TOMOGRAPHY WITH SELECTIVE FFR-CT IN PATIENTS PRESENTING WITH CHEST PAIN IN THE EMERGENCY DEPARTMENT
Authors: Sherin Sallam, Nour Tashtish, Scott E. Janus, Robert Hughes, Imran Rashid, Amit Gupta, Kianoush AnsariGilani, Robert C. Gilkeson, Sanjay Rajagopalan, Sadeer G. Al-Kindi
Journal: Journal of the American College of Cardiology (2022)
UTILITY OF CARDIAC MAGNETIC RESONANCE IMAGING IN ASSESSING SEVERITY OF AORTIC STENOSIS
Authors: Rafey Feroze, Luis Dallan, Varun Rajagopalan, Sunghan Yoon, Craig Jarrett, Sanjay Rajagopalan, Sadeer G. Al-Kindi, Guilherme Attizzani, Imran Rashid
Journal: Journal of the American College of Cardiology (2022)
NON-VITAMIN K ANTAGONISTS VS. WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION AND TRANSCATHETER AORTIC VALVE REPLACEMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Caique M P Ternes, Gustavo Busch Justino, Leonardo Busch Justino, Amanda Fernandes, Gilson Fernandes, Fabrissio P. Graffunder, Rhanderson Cardoso
Journal: Journal of the American College of Cardiology (2022)
MODULATING CARDIAC AUTONOMIC BALANCE BY VAGUS NERVE STIMULATION ATTENUATES MITOCHONDRIAL DYSFUNCTION AND PROVIDES PROTECTION AGAINST TRASTUZUMAB-INDUCED CARDIOTOXICITY
Authors: Nanthip Prathumsap, Benjamin Ongnok, Thawatchai Khuanjing, Apiwan Arinno, Chayodom Maneechote, Nattayaporn Apaijai, Titikorn Chunchai, Busarin Arunsak, Krekwit Shinlapawittayatorn, Siriporn Chattipakorn, Nipon Chattipakorn
Journal: Journal of the American College of Cardiology (2022)
USING QUALITY IMPROVEMENT TOOLS TO DECREASE LENGTH OF STAY AFTER FONTAN SURGERY IN PEDIATRIC PATIENTS WITH SINGLE VENTRICLE - TYPE CONGENITAL HEART DISEASE
Authors: Aarti H. Bhat, Madeleine Charlson, Molly Sumner, Catherine Horner, Plicy Perez, Claudia Sassano, Morgan Clogston, Colin Crook, Emily Rowen, Kihan Kim, Jessica Colyer, Titus Chan, Katherine Banker, Matthew Files, Christa Kirk, D. Michael McMullan, Kenneth Rudberg
Journal: Journal of the American College of Cardiology (2022)
CARDIOGENIC SHOCK DUE TO A FAILED BIOPROSTHETIC VALVE RESULTING IN URGENT TRANSCATHETER MITRAL VALVE-IN-VALVE REPLACEMENT
Authors: Rajeev V. Seecheran, Lawrence Zhou, Rhythm Vasudeva, Abhiram Challa, Venkata C. Boppana, Cyrus Munguti
Journal: Journal of the American College of Cardiology (2022)
IMPACT OF THE COVID-19 PANDEMIC ON HOSPITAL ADMISSIONS AND MORTALITY ASSOCIATED WITH CORONARY EVENTS IN THE BRAZILIAN PRIVATE HEALTH
Authors: Bruno Ramos Nascimento, Luiz Eduardo V. Froes, Ana Cristina T. Castro, Eduardo Tomaz Froes, Luisa Caldeira Brant, Antonio L. Ribeiro, Larissa V. Cruz, Cynthia B. Araújo, Charles F. Souza, Renato A. Teixeira, Andrea Z. Beaton, Craig A. Sable, Felipe L. Gomes, Soraya D. Souza
Journal: Journal of the American College of Cardiology (2022)
MEDICAL TRAINEES PREFER A NOVEL ELECTROCARDIOGRAM(ECG) CURRICULUM, BASED ON TYPE I PROCESSING(TIP)-FOCUSED ECG INSTRUCTION: TIP-ECG
Authors: Maranda Herner, Alexis Z. Tumolo, Adrienne Mann, Jared Bunch, Jack H. Morshedzadeh, Kelsey M. Flint
Journal: Journal of the American College of Cardiology (2022)
INTRAVASCULAR LITHOTRIPSY VERSUS ATHERECTOMY FOR THE TREATMENT OF COMMON FEMORAL ARTERY DISEASE, A RETROSPECTIVE COHORT STUDY
Authors: Muhammad Baig, Michael Kwok, Ammer Aldairi, Hafiz Imran, Mohammad Saud Khan, Kyari S. Ngamdu, S Hammad Jafri, Omar Hyder, Herbert D. Aronow, Peter A. Soukas
Journal: Journal of the American College of Cardiology (2022)